Curcumin for the treatment of major depression
Lopresti AL, Maes M, Maker GL, Hood SD, Drummon PD. 2014. Curcumin for the treatment of major depression: A randomised, double-blind, placebo controlled study. J Affect Disord_167:368-75 doi: 10.1016/j.jad.2014.06.001
The understanding of major depressive disorder (MDD) has increased over recent years, with causative biological disturbances expanding from monoaminergic transmission, particularly serotonin availability, to also include dysregulation in the hypothalamus-pituitary-adrenal (HPA) axis, activation of immune-inflammatory pathways, increased oxidative and nitrosative stress, neuroprogression and mitochondrial dysfunction. Consequently, compounds that act upon these pathways have generated interest in the treatment of major depression.
Curcumin, the main bioactive component of Curcuma longa (turmeric) has been found to influence a number of these pathways. Specifically, it can lower markers of oxidative stress as a potent antioxidant, modulates immune-inflammation by acting as a cox-2 inhibitor and lowering pro-inflammatory cytokines, provides significant neuroprotection, modulates HPA activity, and influences monoamine transmission through an effect on serotonergic and dopaminergic activity. The current study aimed to expand the investigation into the antidepressant effects of curcumin supplementation in people with MDD.
This Australian study was a randomised, double blind, placebo controlled trial in which 56 individuals aged 18-65 years with MDD were treated with curcumin (500mg twice daily) or placebo for 8 weeks. The curcumin contained total curcuminoids 88% (curcumin, bisdemethoxycurcumin, demethyoxycurcumin) and...
You Are Viewing A Preview Page of the Full ArticleThe article found is from the Academic OneFile database.
You may need to log in through your institution or contact your library to obtain proper credentials.